(Total Views: 527)
Posted On: 07/18/2018 2:07:48 PM
Post# of 30070
.jpg)
WuXi Apptec now tweeting out about Amarantus. Next story I saw was this:
Asian VC is coming to bio https://www.biospace.com/article/releases/sta...s-disease/
"In conjunction with this launch, Neuraly has raised a Series A financing of $36 million from holding company, D&D Pharmatech with participation by major Korean venture funds, including: Smilegate Investment, InterVest, LB Investment, Magna Investment, Geon Investment and Dongkoo Bio&Pharma. Two U.S.-based funds, Octave Life Sciences and Maryland Venture Fund, also participated in this financing. In turn, the following representatives will join Seulki Lee, Ph.D., Chairman and Founder, and Viktor Roschke, Ph.D., Co-founder on the Board of Directors: John Ku, Executive Vice President of Smilegate Investment, Phillip Jung, Associate at Maryland Venture Fund, Junghee Lim, Executive Managing Director of InterVest and Keele Park, CEO of Magna Investment."
these deals are worked on in the shadows for months and years. Diff firms team up,
Asian VC is coming to bio https://www.biospace.com/article/releases/sta...s-disease/
"In conjunction with this launch, Neuraly has raised a Series A financing of $36 million from holding company, D&D Pharmatech with participation by major Korean venture funds, including: Smilegate Investment, InterVest, LB Investment, Magna Investment, Geon Investment and Dongkoo Bio&Pharma. Two U.S.-based funds, Octave Life Sciences and Maryland Venture Fund, also participated in this financing. In turn, the following representatives will join Seulki Lee, Ph.D., Chairman and Founder, and Viktor Roschke, Ph.D., Co-founder on the Board of Directors: John Ku, Executive Vice President of Smilegate Investment, Phillip Jung, Associate at Maryland Venture Fund, Junghee Lim, Executive Managing Director of InterVest and Keele Park, CEO of Magna Investment."
these deals are worked on in the shadows for months and years. Diff firms team up,
(2)
(0)
